Medicine

June 03, 2009 -- RICHMOND – Virginia Governor Timothy M. Kaine released the following statement today regarding the Commonwealth's first confirmed death associated with the H1N1 influenza virus commonly known as "swine flu":

"The news today that the Commonwealth has witnessed its first death associated with the H1N1 influenza virus is a sad and sharp reminder that Virginians must remain vigilant against the spread of this potentially fatal illness. My heart goes out to the family and friends of the young woman who passed away this afternoon in Chesapeake.    » read more »

June 3, 2009 -- “It is with deep sadness that we learn that New York has lost an Onondaga County resident to an illness related to the H1N1 influenza. On behalf of all New Yorkers, I extend my sincere condolences and prayers to his family and friends during their time of grief.

“As more cases of H1N1 are identified in New York State, unfortunately, we expect some cases to be fatal, especially for those who contract the virus and have underlying medical conditions. This is consistent with what we see during our influenza season each year. Annually, there are approximately 2,000 deaths in New York State from seasonal influenza and an estimated 36,000 deaths nationwide.    » read more »

The American Recovery and Reinvestment Act of 2009 Will Invest Over $1.3 Million at Medical Research Facilities in Western NY

June 2, 2009 -- U.S. Senators Charles E. Schumer and Kirsten Gillibrand today announced that the American Recovery and Reinvestment Act (ARRA) will provide a total of $1,346,463 to two research institutions in Western NY through the National Institutes for Health. The University at Buffalo will receive $212,022 and the Roswell Park Cancer Institute (RPCI) will receive $1,134,441. This funding will create jobs for those in the field and bolster research efforts on important areas of medicine. A total of $9.9 million will be administered to New York State research institutions.    » read more »

1 June 2009 -- As of 06:00 GMT, 1 June 2009, 62 countries have officially reported 17 410 cases of influenza A(H1N1) infection, including 115 deaths.

The breakdown of the number of laboratory-confirmed cases by country is given in the following table.

Laboratory-confirmed cases of new influenza A(H1N1) as officially reported to WHO by States Parties to the International Health Regulations (2005)    » read more »

Orlando FL, 29 May 2009 -- GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] today announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA™ (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment.    » read more »

Panel Votes in Favor of Use by Physician/Nurse Teams to Deliver Minimal-to-Moderate Propofol Sedation

(May 28, 2009) –Ethicon Endo-Surgery today announced that the Anesthesiology and Respiratory Therapy Devices Advisory Committee of the U.S. Food and Drug Administration (FDA) voted in favor of approval of the SEDASYS® System for use by physician/nurse teams to administer minimal-to-moderate propofol sedation during screening and diagnostic procedures for colorectal cancer (colonoscopy) and the upper gastrointestinal tract (EGD).

The SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, integrates drug delivery and patient monitoring to enable propofol sedation personalized to each patient’s needs.    » read more »

29 May 2009 -- As of 06:00 GMT, 29 May 2009, 53 countries have officially reported 15,510 cases of influenza A(H1N1) infection, including 99 deaths.

The breakdown of the number of laboratory-confirmed cases by country is given in the following table.

Laboratory-confirmed cases of new influenza A(H1N1) as officially reported to WHO by States Parties to the International Health Regulations (2005)    » read more »

27 May 2009 -- As of 06:00 GMT, 27 May 2009, 48 countries have officially reported 13,398 cases of influenza A(H1N1) infection, including 95 deaths.

The breakdown of the number of laboratory-confirmed cases by country is given in the following table.

Laboratory-confirmed cases of new influenza A(H1N1) as officially reported to WHO by States Parties to the International Health Regulations (2005)

Country Cumulative total    » read more »

Failure to Investigate or Report Cases of Doctor Wrongdoing Endangers Patients

May 27, 2009 -- WASHINGTON, D.C. – Though a federal law requires hospitals to report physicians who have had their admitting privileges revoked or restricted for more than 30 days, a Public Citizen report released today found that in addition to inadequate discipline of physicians, hospitals routinely exploit loopholes to avoid government requirements, with nearly half of all hospitals not submitting a single doctor’s name to the National Practitioner Data Bank (NPDB) in the more than 17 years it has existed.    » read more »

Company to take first steps toward large-scale production

Lyon, France and Swiftwater, Pa - May 27, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today it has received the new influenza A(H1N1) seed virus, enabling the world’s leading manufacturer of influenza vaccines to begin the production process for an A(H1N1) vaccine.

The emergence of a new A(H1N1) virus strain recently led the World Health Organization (WHO) to declare a Level 5 pandemic alert, following human-to-human spread of the virus into at least two countries in one WHO region.    » read more »

As Confirmed Cases of the Virus Continue to Rise, Funding Necessary to Address Budgetary Shortages That Threaten Local, State, and National Response Efforts

May 27, 2009 -- Today, U.S. Senators Charles E. Schumer and Kirsten Gillibrand announced their push to include no less than $350 million in the final Supplemental Appropriations bill to upgrade state and local ability to prepare for and respond to the 2009 H1N1 influenza virus and other potential pandemics.    » read more »

26 May 2009 -- As of 06:00 GMT, 26 May 2009, 46 countries have officially reported 12 954 cases of influenza A(H1N1) infection, including 92 deaths.

The breakdown of the number of laboratory-confirmed cases by country is given in the following table:

Laboratory-confirmed cases of new influenza A(H1N1) as officially reported to WHO by States Parties to the International Health Regulations (2005)    » read more »

May 26, 2009 -- By sequencing the genomes of more than 50 samples of the new A(H1N1) influenza virus, researchers have found that it is distantly related to its nearest relatives, indicating that its genes have been circulating undetected for an extended period. The findings suggest that in the future pig populations will need to be closely monitored for emerging influenza viruses.

Completed by an international team of investigators from the United States, the United Kingdom and Mexico, the research was made available for immediate release 22 May 2009, following acceptance by Science. Journal editors provided free public access to the findings, in light of public health concerns regarding the A(H1N1) virus.    » read more »

Initial U.S. order for bulk vaccine valued at $190 million

Swiftwater, Pa. and Lyon, France – May 25, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.    » read more »

22 May 2009 -- GSK announced today that the US Department of Health and Human Services (HHS) has placed initial orders for A (H1N1) influenza vaccine antigen and the company’s proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts.

GSK manufactures both a traditional vaccine antigen, which will be made from the recently isolated A (H1N1) influenza strain, as well as an adjuvant system. An adjuvant system can be added to the antigen at time of administration.

GSK expects to fill the US adjuvant order within the next few months. The first doses of the vaccine antigen are expected to be available four to six months after the company receives the H1N1 seed strain, subject to regulatory approval. The new vaccine will be tested in clinical trials.    » read more »